ライフサイエンスコーパス: blocking antibody

1 atidylinositol-3 kinase inhibitor and by MET-blocking antibody.

2 IGF-1, growth hormone, and an IGF-1 receptor-blocking antibody.

3 PV-specific T-cell assays in the presence of blocking antibody.

4 alanine completely abolished binding of the blocking antibody.

5 in a manner that was abrogated by anti-PD-L1 blocking antibody.

6 complex with two distinct antagonists and a blocking antibody.

7 ein of P. falciparum can induce transmission-blocking antibody.

8 elease was inhibited by a specific anti-CCR4 blocking antibody.

9 ented by an anti-HCV envelope glycoprotein 2-blocking antibody.

10 by the JNK inhibitor or an anti-DCC function-blocking antibody.

11 eletion of the HA-binding LINK domain, or HA-blocking antibody.

12 , and this inhibition is reduced by the CS-E blocking antibody.

13 ented by preincubation with a beta1-integrin blocking antibody.

14 yte binding, which is blunted by anti-CD44v7 blocking antibody.

15 e media, C3- and C5-deficient sera, and a C5-blocking antibody.

16 on NRP2 as shown using shRNAs and a function-blocking antibody.

17 following pretreatment with an IL6 receptor-blocking antibody.

18 ion were inhibited by an anti-Flk-1 receptor-blocking antibody.

19 AB391R, with resistance to MAB391, an IGF-IR-blocking antibody.

20 treatment enhanced the efficacy of anti-PD-1 blocking antibody.

21 nuated with Cx43(E2), a specific hemichannel-blocking antibody.

22 This effect was mitigated by NKG2D-blocking antibody.

23 erum from each patient with or without Ang-2-blocking antibody.

24 t in UPAR positive cells blocked with a UPAR-blocking antibody.

25 resence or absence of anti-TLR2 or anti-TLR4 blocking antibodies.

26 oaded HDL, S1P receptor antagonists, and S1P-blocking antibodies.

27 ot receive vemurafenib nor immune checkpoint-blocking antibodies.

28 its natural IgA isotype were the most potent blocking antibodies.

29 f vaccines, which should avoid inducing such blocking antibodies.

30 enic NMO-IgG autoantibodies into therapeutic blocking antibodies.

31 attenuated by pretreatment with alphavbeta6-blocking antibodies.

32 ignal significantly decreased (P < 0.001) by blocking antibodies.

33 ins was probed using specific inhibitors and blocking antibodies.

34 the development of paralogue-specific ligand-blocking antibodies.

35 enerated to SD1+2 and SD2 failed to generate blocking antibodies.

36 a9beta1 or treated with integrin alpha9beta1-blocking antibodies.

37 oth processes were neutralized by E-selectin-blocking antibodies.

38 and (4) dependency on IL-4 by treatment with blocking antibodies.

39 C activity were measured with and without ER-blocking antibodies.

40 e proof of concept for a therapy of NMO with blocking antibodies.

41 t has the capacity to induce highly adhesion-blocking antibodies.

42 enic NMO-IgG autoantibodies into therapeutic blocking antibodies.

43 uld be significantly (P = .026) decreased by blocking antibodies.

44 elopment efforts focusing on antagonists and blocking antibodies.

45 axis, partially inhibited by antihuman CXCR3 blocking antibodies.

46 , and functional activity was assessed using blocking antibodies.

47 their ability to induce malaria transmission-blocking antibodies.

48 On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be

49 n was inhibited by an alphavbeta6/8 integrin blocking antibody (264RAD) and a small molecule inhibito

50 ll molecule GRP blocking agent 77427, or GRP blocking antibody 2A11, before exposure to ozone or OVA

51 at this response can be inhibited by the Shh-blocking antibody 5E1 indicates that the Shh response in

52 pecific immunotherapy (AIT) induces specific blocking antibodies (Ab), which are claimed to prevent I

53 A LIF-blocking antibody abolished C26 CM-induced STAT reporter

54 Acute treatment of slices with function-blocking antibodies (Abs) against Nogo-A or against NgR1

55 cal development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discu

56 ibition were evaluated in vivo with anti-NGF blocking antibodies administered both in rat chronic hyp

57 IFN-gamma blocking antibody administered to Sphk2(-/-) mice or del

58 f scavenger receptor class B, galectin-3, or blocking antibodies against CD36, suggesting that pyrral

59 Blocking antibodies against CD55 or virus envelope glyco

60 RETR, antagonized IL-2 and IL-15 better than blocking antibodies against IL-2Ralpha or IL-2Rbeta.

61 specific antieosinophil therapies, including blocking antibodies against IL-5, IL-13, IL-33, and thym

62 id during development, an event prevented by blocking antibodies against p75 neurotrophin receptor (p

63 observations in cancer clinical trials using blocking antibodies against PD-1 or CTLA4, or both, show

64 xidative burst in the presence or absence of blocking antibodies against PD1 or TIM3.

65 r cells, and preincubation of platelets with blocking antibodies against platelet adhesion molecules

66 owth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that pros

67 after peripheral administration, functional blocking antibodies against RANTES and eotaxin reduced t

68 Immunotherapy using checkpoint-blocking antibodies against targets such as CTLA-4 and P

69 fferentiation, PD-L1-deficient RPE cells and blocking antibodies against TGF-beta, CTLA-2alpha, and I

70 signaling, as discovered by pretreatment of blocking antibodies against Toll-like receptors (TLRs) a

71 of Tck cells, which could be abrogated using blocking antibodies against VLA-4.

72 A blocking antibody against (ILFA1), disrupting the lympho

73 Elvax resin implants filled with either a blocking antibody against BDNF or the BDNF protein were

74 Finally, a blocking antibody against beta8 inhibited immunosuppress

75 Intraparenchymal infusion of a blocking antibody against the CX(3)CL1 receptor, CX(3)CR

76 Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1

77 FGFR1 inhibitor, SU5402 or an FGFR3 function-blocking antibody also slowed neural crest migration.

78 Using receptor-blocking antibodies and activation peptides, we determin

79 ling to unmask the binding sites for albumin blocking antibodies and albumin on the receptor, which r

80 s reduced to control cell levels by integrin-blocking antibodies and by inhibition of FAK.

81 The mechanisms were investigated using blocking antibodies and cells isolated from cytokine-def

82 soluble E2 with a lower affinity than other blocking antibodies and do not neutralize virus.

83 gated by septin immunodepletion and function-blocking antibodies and is induced by recombinant septin

84 Here we show that NRP1-blocking antibodies and NRP1 silencing can counteract li

85 Here, using blocking antibodies and pharmacological inhibitors, we d

86 mimics the native trimer might elicit entry-blocking antibodies and prevent virus infection.

87 on, assays were performed in the presence of blocking antibodies and/or small-molecule inhibitors tar

88 ted mice were treated with an IL-10 receptor blocking antibody and a TLR-9 agonist, and parameters of

89 tivated receptor (PAR)-2 was evaluated using blocking antibody and dedicated lentiviral small hairpin

90 ectly targeted NET components with a histone blocking antibody and DNase1, both of which protected mi

91 on is also reduced in the presence of a CD44-blocking antibody and is associated with a specific incr

92 Using functional blocking antibody and RNAi, we further demonstrate that

93 production of IgG4 isotype allergen-specific blocking antibodies, and decreased allergic inflammatory

94 ys in vivo hypoallergenicity, induces potent blocking antibodies, and is captured by human DCs much m

95 ity, its capacity for eliciting transmission-blocking antibodies, and its apparent lack of immunizati

96 poptosis was attenuated by BAPTA, VIVIT, Fas blocking antibody, and a caspase-3/7 inhibitor.

97 a protective role in allergy by acting as a blocking antibody, and inhibiting mast cell degranulatio

98 cking the PS/MFG-E8/VR pathway (by adding PS blocking antibodies, annexin V, mutant MFG-E8 unable to

99 To restore T-cell responses, blocking antibodies (anti-cytotoxic T-lymphocyte antigen

100 (a known CD206 ligand), free mannose, and a blocking antibody (anti-hMR).

101 We also show that a blocking antibody antigen-binding fragment binds to the

102 squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatmen

103 Thus, ADCC-defective Fn14-blocking antibodies are not only possible novel GVL effe

104 ecause of the recent development of anti-NGF blocking antibodies as a possible new pain treatment, su

105 Nase L activation in BMM treated with IFNAR1-blocking antibody, as well as in Ifnar1(-/-) BMM, both e

106 nd safety of pembrolizumab, a humanized PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in

107 eous CKD, therapeutic delivery of anti-TWEAK blocking antibodies attenuated disease progression, pres

108 locked by intratumoral injection of the VEGF-blocking antibody Avastin (bevacizumab), pharmacologic P

109 In contrast to normal B7-H1 blocking antibody, B7-H1 antibodies capable of activatin

110 Treatment of Tregs with a PD-1 blocking antibody before adoptive transfer reversed thei

111 likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.

112 temic administration of anti-C5- or anti-C5a-blocking antibodies blunted the CNV-induced production o

113 nt also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.

114 ed the growth inhibition in response to AREG-blocking antibodies but not to shRNA-mediated AREG knock

115 Checkpoint-blocking antibodies can generate potent anti-tumor respo

116 When isolated without the use of blocking antibodies, CD41+ HSCs possessed long-term repo

117 n JAG2-deficient thymic lobes or with Notch3-blocking antibodies confirm the importance of Jagged2/No

118 Blocking antibodies correlate with protection against cl

119 a specific IgG4 response, and production of blocking antibodies correlated with TH2 response downreg

120 er-derived galectin-1 on DCs and anti-HB-EGF blocking antibodies could, therefore, have therapeutic p

121 We hypothesized that nivolumab, a PD-1-blocking antibody, could inhibit tumor immune evasion in

122 eutic effect of the humanized anti-Jagged1/2-blocking antibody CTX014 on MDSC-mediated T-cell suppres

123 y was long lasting, with homologous receptor-blocking antibodies detected throughout the lifespan of

124 P-HBGA interaction, while an anti-GII.4-2006 blocking antibody did not, indicating that epitope A ami

125 MT1-MMP-blocking antibodies diminished migration, proliferation,

126 , differential and sequential treatment with blocking antibodies directed against PVR, DNAM-1, PECAM,

127 ceptor protected mice after treatment with a blocking antibody directed against PD-1.

128 Further, we show that VEGFR-2 and VEGFR-1 blocking antibodies displayed opposing effects on tumor

129 the therapeutic potential of using an IL-25 blocking antibody during a chronic inflammatory setting.

130 cgammaRIIB-transgenic (Tg) mice, FcgammaRIIB-blocking antibodies effectively deleted target cells in

131 either by silencing or the use of a function blocking antibody efficiently reduces EGF/EGFR-induced c

132 Atf4(-/-) bone marrow stromal cells and Ihh-blocking antibody eliminates this effect.

133 By comparison, the TNFalpha-blocking antibody Enbrel had no effect on IAP inhibitor/

134 oradiotherapy, and ex vivo culture with PD-1-blocking antibody enhanced HPV-specific T-cell responses

135 n of VE-cadherin clustering at AJs (function-blocking antibody, FBA) inhibited dilatation to acetylch

136 n clustering at adherens junctions (function-blocking antibody; FBA) reduced endothelial dilatation i

137 survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade.

138 nd that a short course of anti-IL-7 receptor blocking antibody following T cell depletion, combined w

139 tor N-hydroxy-nor-l-arginine (nor-NOHA), and blocking antibodies for IL-4Ralpha(+) and IL-10.

140 ns in trophoblasts were determined using two blocking antibodies for measuring migration and prolifer

141 ine loops of death receptor ligands, because blocking antibodies for TNFalpha, tumor necrosis factor-

142 tory role because of the noninflammatory and blocking antibody function of IgG4.

143 oglycans, as demonstrated by the use of CS-E blocking antibody GD3G7.

144 sis of tumor cells mediated by CD47-specific blocking antibodies has been proposed to be the major ef

145 Systemic blocking of CTLA4 function with blocking antibodies has been regarded as an attractive s

146 s recognized by current therapeutic function-blocking antibodies has resulted in previously unanticip

147 tion of regulatory lymphocyte subsets and of blocking antibodies have been described.

148 B7-H1 (aka PD-L1) blocking antibodies have been used in treatment of human

149 te its ability to induce high-titer invasion-blocking antibodies in a controlled human challenge tria

150 Using gene deletion and function-blocking antibodies in mice, we determined that the lymp

151 Using both genetic mutants and blocking antibodies in mice, we show that retinoic acid

152 l significance was assessed by silencing and blocking antibodies in several in vivo models of lung ca

153 sion was as effective as anti-PD-1 and PD-L1-blocking antibodies in the control of B16 melanoma, or E

154 Administration has approved three checkpoint-blocking antibodies in three disease indications, and ad

155 Js using a calcium-switch assay and cadherin-blocking antibodies indicates direct recruitment of ROCK

156 Thus, SD3 binds Fy and elicits blocking antibodies, indicating that it contains residue

157 of breast cancer cells to cetuximab (an EGFR-blocking antibody)-induced inhibition of cell signaling

158 tion was demonstrated in vitro, as TNF-alpha blocking antibodies inhibited downstream CD8(+) T cell a

159 Here we found that an ANG2-blocking antibody inhibited embryonic lymphangiogenesis,

160 Targeting of CD47 with a blocking antibody inhibited Raji cell dissemination to m

161 e with therapeutic intent-for example, using blocking antibodies inhibiting PD-1/PD-L1 (programmed de

162 While infusion of IL-10R blocking antibody, initiated at day 60, caused a signifi

163 Notably, injection of LIF-blocking antibody into PDAC-bearing mice reduced intratu

164 lerosis (MS) during treatment with the CTLA4-blocking antibody ipilimumab for metastatic melanoma.

165 he cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab results in durable response

166 ence with the Dll4 signal by ligand-specific blocking antibodies is sufficient to inhibit the endothe

167 IgG4 is a blocking antibody isotype with anti-inflammatory potenti

168 were attenuated by the Fcgamma receptor IIa-blocking antibody IV.3, suggesting they are mediated by

169 Injections of mouse neonates with BMP9/10 blocking antibodies lead to HHT-like vascular defects in

170 shot with small RNA interference or function-blocking antibody led to a dramatic reduction of AMPA re

171 genesis that, when interrupted by PDGFRalpha-blocking antibody, led to decreased hepatoblast prolifer

172 Changes in sIgE levels and reduced IL-4 and blocking antibody levels could thus be used as indicator

173 es from baseline in cockroach IgE, IgG4, and blocking antibody levels.

174 The application of blocking antibodies may be an alternative treatment stra

175 0.47; P = .01), and treatment with the CD49d-blocking antibody natalizumab resulted in significantly

176 ogrammed cell death protein 1 (PD-1) pathway-blocking antibody nivolumab has shown substantial therap

177 n cancer therapy to a similar degree as PD-1 blocking antibodies, offering a next-generation approach

178 with CD was reduced by EGF receptor and IL15 blocking antibodies only when used in combination.

179 Moreover, angiogenin antagonism by blocking antibodies or angiogenin inhibitor neomycin dec

180 However, inhibition of VEGFR1 activity by blocking antibodies or by genetic deletion of the tyrosi

181 re not observed in mice pretreated with CD36 blocking antibodies or in CD36(0/0) mice.

182 rimental ICV either in mice treated with VWF-blocking antibodies or in VWF(-/-) mice.

183 types can phagocytose PMPs, and by using TAM-blocking antibodies or siRNA knockdown of individual TAM

184 alpha3 but not alpha6 integrin subunit using blocking antibodies or small interfering RNA abrogated t

185 In a murine model, administration of CD47-blocking antibodies or targeted inactivation of the Cd47

186 uld be mitigated by addition of either a Fas blocking antibody or a caspase-3 inhibitor.

187 tion of endothelial activation with a VCAM-1 blocking antibody or a VAP-1 small molecule inhibitor le

188 g, either by injections of low dose of ICOSL blocking antibody or by halving the gene dose of Icos in

189 hich could be blocked by selective ITGalpha6 blocking antibody or iNOS inhibitors.

190 Treatment with an IFN-beta receptor blocking antibody or knockdown of IFN-beta significantly

191 Further, by using a nectin-4 blocking antibody or recombinant MeV unable to enter cel

192 Treating neurons with a CD44-blocking antibody or short hyaluronan oligosaccharides,

193 However, the addition of neuropilin 1 (Nrp1)-blocking antibody or siRNA knockdown of Nrp1 inhibits Se

194 Treatment with either an anti-alphaVbeta6 blocking antibody or soluble transforming growth factor-

195 Attenuation of RNLS by RNAi, blocking antibodies, or an RNLS-derived inhibitory pepti

196 PD-1 inhibition on melanoma cells by RNAi, blocking antibodies, or mutagenesis of melanoma-PD-1 sig

197 de, preincubating platelets with a TGF-beta1-blocking antibody, or reducing expression of TGF-betaR1

198 HMGB1 depletion, HMGB1 blocking antibody, or TLR-4 inhibition attenuated senesc

199 nizing Siglec-8 in combination with integrin blocking antibodies, pharmacologic inhibitors, phosphopr

200 Treatment with a poliovirus receptor-blocking antibody phenocopied the protective effect of i

201 roconversion and a corresponding increase in blocking antibody potential was observed.

202 In vivo, we demonstrated that anti-NGF blocking antibodies prevent and reverse PH in rats throu

203 , endothelin receptor antagonists and/or KIT blocking antibodies prevent precocious melanocyte stem c

204 In cultured endothelial cells, FcgammaRI-blocking antibodies prevented CRP antagonism of eNOS, an

205 FcgammaRIIB-blocking antibodies prevented internalization of the CD2

206 Consequently, treatment with Notch1 or VCAM1-blocking antibodies prevented Notch-driven metastasis, a

207 While c-kit blocking antibodies prevented spreading, imatinib blocke

208 grin alphaVbeta3 receptor, whereas periostin-blocking antibody prevented inhibition of MEF2C and Sost

209 antly, therapeutic intervention by IFN-gamma blocking antibody prevented neuronal deafferentation and

210 In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients

211 lls, either with cyclosporine A or anti-CD1d blocking antibody, prolonged mice survival.

212 Furthermore, RGMa blocking antibodies promoted neuronal survival, and enha

213 Treatment with a CD47-blocking antibody protected mice from renal dysfunction

214 Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhib

215 We have generated blocking antibodies, raised in Eda-deficient mice, again

216 ory bulb and dentate gyrus, whereas specific blocking antibodies reduce the number of stem/progenitor

217 istration of either of two distinct function-blocking antibodies reduced the suppression of Tie2 phos

218 Furthermore, exposure to a MFGE8-blocking antibody reduces phagocytic activity.

219 RATIONALE: Mepolizumab, an IL-5-blocking antibody, reduces exacerbations in patients wit

220 Therapeutic strategies using anti-PD-1-blocking antibodies reported unparalleled effectiveness

221 ution approaches, inhibitors, and functional blocking antibodies, respectively.

222 ects (P = .09) but no evidence of functional blocking antibody response.

223 LR2 knockout mice developed TLR2-independent blocking antibody responses with similar kinetics.

224 , as well as histoblood group antigen (HBGA) blocking antibody responses, were measured before and af

225 T, especially with regard to IgG4 levels and blocking antibody responses.

226 A CDH1 function-blocking antibody restores prostatic identity, bud outgr

227 Use of CD18 blocking antibodies resulted in reduction of human plate

228 ment of ovarian tumor-bearing mice with PD-1 blocking antibody resulted in an increase in IL10 levels

229 ng, by addition of cyclopamine or a function-blocking antibody, resulted in large, ectopic ganglia ad

230 ctive inhibition of EphB4 using a functional blocking antibody results in defective lymphatic valve d

231 e of Notch1 and Dll4, with specific function-blocking antibodies, results in defective postnatal lymp

232 Experiments with knockout mice and blocking antibodies reveal that the uropod elongation an

233 IL-9-blocking antibodies reversed this tumor growth inhibitio

234 ibition of Wnt5a by either RNAi knockdown or blocking antibody reversed Smarcd3/Baf60c-induced EMT.

235 Furthermore, administration of VEGFR blocking antibody selectively improved survival of Shh-d

236 Rats treated with RGMa blocking antibodies showed significantly improved recove

237 n cancer therapy to a similar degree as PD-1-blocking antibodies.Significance: These findings show ho

238 , -beta3, and -alphavbeta3 integrin function-blocking antibodies significantly inhibited the galectin

239 Addition of anti-B7-H1 blocking antibody significantly reversed the inhibitory

240 Treatment with VEGF or VEGFR-2 blocking antibodies similarly reduced tumor angiogenesis

241 Administration of blocking antibodies specifically against CTGF domain 4 o

242 Function blocking antibody studies revealed haptokinetic spreadin

243 By relieving this restraint, CTLA-4-blocking antibodies such as ipilumimab can promote tumor

244 supernatants and its abrogation by anti-TrkB blocking antibody suggest that NaPB-induced astroglial n

245 Previous studies using blocking antibodies suggested that bone marrow (BM)-deri

246 e unaffected by pretreatment with a receptor-blocking antibody, suggesting that oxidative stress acti

247 atment of established tumours with ephrin-B2-blocking antibodies suppressed progression.

248 on of extracellular reelin with CR-50 reelin-blocking antibodies suppressed the increase in migratory

249 A SNAP-25 peptide and function-blocking antibody suppressed PKC potentiation of NMDA EP

250 echanisms of glucagon receptor inhibition by blocking antibodies targeting the receptor's extracellul

251 anism of the Fv and Fc portions of anti-TLR4 blocking antibodies that achieves increased potency on i

252 In the presence of a DAF-blocking antibody, the reduction in C3b deposition was r

253 as no corresponding increase in the specific blocking antibody titer.

254 Most subjects achieved HBGA-blocking antibody titers of >/=200.

255 Conversely, function-blocking antibodies to alpha5 and beta1 integrin sub-uni

256 xamined by comparing the effects of function-blocking antibodies to Ang2 or TNF, given individually o

257 esion in the presence of fibrinogen, whereas blocking antibodies to anubeta3 integrin on melanoma cel

258 Treatment with blocking antibodies to CD1a alleviated skin inflammation

259 porting system was exemplified by generating blocking antibodies to FGF4 and its receptor FGFR1beta,

260 T binding at this site in cells treated with blocking antibodies to IL-2 and the IL-2 receptor, sugge

261 these clones because it could be reduced if blocking antibodies to IL-4 were present.

262 AT3 phosphorylation, and myotube atrophy but blocking antibodies to IL-6 or OSM did not.

263 from stool required the addition of cytokine-blocking antibodies to interrupt downstream antiviral pa

264 Importantly, blocking antibodies to osteopontin mitigated but did not

265 result was supported by the observation that blocking antibodies to OX40 and CD30 ligands also abroga

266 neurons or slices after delivery of function-blocking antibodies to p75(NTR) or proNGF and in p75(NTR

267 study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels

268 Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1 has pr

269 Moreover, administration of EDA blocking antibodies to pregnant wild type mice induced i

270 nduced T cell costimulation was inhibited by blocking antibodies to Toll-like receptor 2 (TLR2) and T

271 Blocking antibodies to Toll-like receptor 4 inhibited bo

272 This priming effect was inhibited by blocking antibodies to TSLPR and ST2, respectively, and

273 ction by intraperitoneal administration of a blocking antibody to 6 week-old female NOD/ShiLtJ mice r

274 Treatment with a blocking antibody to CD44 reduced lung fibrosis in mice

275 of multiple sclerosis (MS), we administered blocking antibody to CLEC12A that significantly ameliora

276 hermore, administration of glucagon receptor-blocking antibody to healthy individuals increased plasm

277 tion in AKI, we utilized a specific function-blocking antibody to inhibit alphavbeta5 in a rat model

278 The in vivo administration of a blocking antibody to OX40L in wild-type mice caused enha

279 Glycyrrhizin, a chelator of HMGB-1 and a blocking antibody to receptor for advanced glycation end

280 s essential residues that can be targeted by blocking antibody to reduce infection, and determines th

281 re unaltered by the addition of a functional blocking antibody to the IGF-1R.

282 ergic transmission as well as a functionally blocking antibody toward the pan-neurotrophin receptor p

283 g down PD-1 expression or by using anti-PD-1 blocking antibodies, translated in vivo into better clea

284 s with advanced melanoma receiving the CTLA4-blocking antibody tremelimumab, allowing the analysis of

285 hrough RNA interference, specific N-terminus-blocking antibodies, Tyro3 phosphorylation, and Tyro3-,

286 malization of blood glucose levels with GCGR-blocking antibody unexpectedly doubled beta-cell mass re

287 The efficacy of the blocking antibodies was studied using cell culture, spin

288 A locally injected TNF blocking antibody was also able to inhibit neutrophil-de

289 Using knockout mice and blocking antibodies, we found that mucin-triggered cathe

290 Finally, using functional blocking antibodies, we identified E-cadherin as a major

291 ubsequent peptide epitope mapping of a NKp30 blocking antibody, we have identified a critical ligand

292 lar front migration was observed when Angpt2 blocking antibodies were administered to Tie1-deficient

293 rties to activate specific T cells or induce blocking antibodies were conserved.

294 ytes, monocytes, and macrophages, and CX3CL1-blocking antibodies were used to assess its role in mono

295 Blocking antibodies were used to dissect the role of Tol

296 We generated a new Met-blocking antibody which binds outside the ligand-binding

297 ptive transfer of Emicro-TCL1 CLL with PD-L1-blocking antibodies, which prevented CLL development and

298 Combination of the anti-DCC function-blocking antibody with expression of DSCAM shRNA in prim

299 d CD8(+) T cells and administration of a PD1-blocking antibody with TEGVAX elicited complete regressi

300 Application of an IL-17A-blocking antibody within 3 hours after stroke induction